+

WO2009004247A3 - Inhibiteurs de tace dans le traitement de l'acne - Google Patents

Inhibiteurs de tace dans le traitement de l'acne Download PDF

Info

Publication number
WO2009004247A3
WO2009004247A3 PCT/FR2008/051085 FR2008051085W WO2009004247A3 WO 2009004247 A3 WO2009004247 A3 WO 2009004247A3 FR 2008051085 W FR2008051085 W FR 2008051085W WO 2009004247 A3 WO2009004247 A3 WO 2009004247A3
Authority
WO
WIPO (PCT)
Prior art keywords
acne
treatment
tace inhibitors
expression
activity
Prior art date
Application number
PCT/FR2008/051085
Other languages
English (en)
Other versions
WO2009004247A2 (fr
Inventor
Jerome Aubert
Isabelle Carlavan
Johannes Voegel
Original Assignee
Galderma Res & Dev
Jerome Aubert
Isabelle Carlavan
Johannes Voegel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev, Jerome Aubert, Isabelle Carlavan, Johannes Voegel filed Critical Galderma Res & Dev
Priority to EP08806020A priority Critical patent/EP2160606A2/fr
Priority to CA2690593A priority patent/CA2690593A1/fr
Priority to JP2010512749A priority patent/JP2010532658A/ja
Publication of WO2009004247A2 publication Critical patent/WO2009004247A2/fr
Publication of WO2009004247A3 publication Critical patent/WO2009004247A3/fr
Priority to US12/640,029 priority patent/US20100168089A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à inhiber l'expression ou l'activité de TACE, ainsi que l'utilisation d'inhibiteurs de l'expression ou de l'activité de cette enzyme pour le traitement de l'acné.
PCT/FR2008/051085 2007-06-18 2008-06-18 Inhibiteurs de tace dans le traitement de l'acne WO2009004247A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08806020A EP2160606A2 (fr) 2007-06-18 2008-06-18 Inhibiteurs de tace dans le traitement de l'acne
CA2690593A CA2690593A1 (fr) 2007-06-18 2008-06-18 Inhibiteurs de tace dans le traitement de l'acne
JP2010512749A JP2010532658A (ja) 2007-06-18 2008-06-18 ざ瘡の治療におけるｔａｃｅインヒビター
US12/640,029 US20100168089A1 (en) 2007-06-18 2009-12-17 Utilization of tace inhibitors for the treatment of acne

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0755819 2007-06-18
FR0755819A FR2917427B1 (fr) 2007-06-18 2007-06-18 Inhibiteurs de tace dans le traitement de l'acne

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/640,029 Continuation US20100168089A1 (en) 2007-06-18 2009-12-17 Utilization of tace inhibitors for the treatment of acne

Publications (2)

Publication Number Publication Date
WO2009004247A2 WO2009004247A2 (fr) 2009-01-08
WO2009004247A3 true WO2009004247A3 (fr) 2009-04-30

Family

ID=38961832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/051085 WO2009004247A2 (fr) 2007-06-18 2008-06-18 Inhibiteurs de tace dans le traitement de l'acne

Country Status (6)

Country Link
US (1) US20100168089A1 (fr)
EP (1) EP2160606A2 (fr)
JP (2) JP2010532658A (fr)
CA (1) CA2690593A1 (fr)
FR (1) FR2917427B1 (fr)
WO (1) WO2009004247A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275108A1 (en) * 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
WO2016092493A1 (fr) * 2014-12-12 2016-06-16 Glaxosmithkline Intellectual Property Development Limited Nouvelle méthode d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042436A1 (fr) * 1998-02-19 1999-08-26 American Cyanamid Company Alkyle, aryle ou heteroarylamides n-hydroxy-2-(alkyl, aryl ou heteroaryl sulfanyl, sulfinyl ou sulfonyl)-3-substitues en tant qu'inhibiteurs de la metalloproteinase matricielle
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
WO2006002057A2 (fr) * 2004-06-15 2006-01-05 Advanced Biotherapy, Inc. Traitement de l'acne

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018326A1 (fr) * 2000-08-31 2002-03-07 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'acide propenohydroxamique
JP2004107220A (ja) * 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
US20060286108A1 (en) * 2005-06-16 2006-12-21 Bell Katherine A Topical compositions for the treatment of chronic wounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042436A1 (fr) * 1998-02-19 1999-08-26 American Cyanamid Company Alkyle, aryle ou heteroarylamides n-hydroxy-2-(alkyl, aryl ou heteroaryl sulfanyl, sulfinyl ou sulfonyl)-3-substitues en tant qu'inhibiteurs de la metalloproteinase matricielle
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
WO2006002057A2 (fr) * 2004-06-15 2006-01-05 Advanced Biotherapy, Inc. Traitement de l'acne

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BECHERER J D ET AL.: "Chapter 13: The tumor necrosis factor-alpha converting enzyme", 2000, HANDBOOK OF EXPERIMENTAL PHARMACOLOGY; PROTEASES AS TARGETS FOR THERAPY; SERIES : HANDBOOK OF EXPERIMENTAL PHARMACOLOGY (ISSN 0171-2004), PAGE(S) 235-258, SPRINGER-VERLAG {A}, HEIDELBERGER PLATZ 3, D-14197, BERLIN, GERMANY, ISSN: 3-540-66118-2, XP009095795 *
KILE R L: "The treatment of acne with TACE.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 21, no. 2, August 1953 (1953-08-01), pages 79 - 81, XP009095116, ISSN: 0022-202X *

Also Published As

Publication number Publication date
EP2160606A2 (fr) 2010-03-10
FR2917427B1 (fr) 2009-08-21
CA2690593A1 (fr) 2009-01-08
JP2010532658A (ja) 2010-10-14
US20100168089A1 (en) 2010-07-01
JP2014051500A (ja) 2014-03-20
WO2009004247A2 (fr) 2009-01-08
FR2917427A1 (fr) 2008-12-19

Similar Documents

Publication Publication Date Title
UA96126C2 (ru) Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы
WO2009129335A3 (fr) Inhibiteurs sélectifs de l'histone désacétylase
NO20092569L (no) Inhibitorer av Akt-aktivitet
WO2007026251A8 (fr) Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
WO2006078752A3 (fr) Inhibiteurs d'adn-methyltransferase
WO2007059230A3 (fr) 1h-benzimidazole-4-carboxamides substitues efficaces en tant qu’inhibiteurs de parp
MX2009011210A (es) Inhibidores de mcl1 de indol 7-no sustituido.
WO2010074588A3 (fr) Composés pharmaceutiques
WO2009001097A3 (fr) Thérapie par réduction de substrat
WO2007092622A3 (fr) Compositions et méthodes pour le traitement d'os
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
WO2011022489A3 (fr) Composés (bis)urée et (bis)thiourée en tant que modulateurs épigéniques de la déméthylase 1 spécifique à la lysine et méthodes de traitement de troubles
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2008131000A3 (fr) Inhibiteurs mcl-1 indole 7-substitués
WO2007123892A3 (fr) Inhibiteurs raf et leurs utilisations
WO2009114725A3 (fr) Mobilisation de cellules souches hématopoïétiques
WO2008073452A8 (fr) Compositions, synthèse et procédés d'utilisation d'inhibiteurs de cholinestérase à base d'indanone
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2009027346A3 (fr) Inhibiteurs 17bêta-hydroxystéroïd-déhydrogénase de type 1 pour traiter des maladies hormono-dépendantes
WO2008106594A3 (fr) Inhibiteurs de la nucléophosmine (npm) et procédés d'induction de l'apoptose
ZA200802848B (en) Potassium channel inhibitors
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2008073332A3 (fr) Compositions de créatine pour traitement cutané
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08806020

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008806020

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2690593

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010512749

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载